Prescient Therapeutics (ASX:PTX) Price-to-Operating-Cash-Flow : (As of May. 11, 2024)

View and export this data going back to 1986. Start your Free Trial

What is Prescient Therapeutics Price-to-Operating-Cash-Flow?

As of today (2024-05-11), Prescient Therapeutics's share price is A$0.041. Prescient Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.01. Hence, Prescient Therapeutics's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for Prescient Therapeutics's Price-to-Operating-Cash-Flow or its related term are showing as below:

ASX:PTX's Price-to-Operating-Cash-Flow is not ranked ^*
in the Biotechnology industry.
Industry Median: 26.92
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

Prescient Therapeutics's Cash Flow from Operations per share for the six months ended in Dec. 2023 was A$-0.00. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.01.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -14.50% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 8.70% per year. During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 28.10% per year.

During the past 13 years, Prescient Therapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 72.80% per year. The lowest was -17.40% per year. And the median was 19.80% per year.

Prescient Therapeutics Price-to-Operating-Cash-Flow Historical Data

The historical data trend for Prescient Therapeutics's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prescient Therapeutics Price-to-Operating-Cash-Flow Chart

Prescient Therapeutics Annual Data

Trend

Jun13

Jun14

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Price-to-Operating-Cash-Flow

Get a 7-Day Free Trial

Prescient Therapeutics Semi-Annual Data
	Dec13	Jun14	Dec14	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Price-to-Operating-Cash-Flow	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Prescient Therapeutics's Price-to-Operating-Cash-Flow

For the Biotechnology subindustry, Prescient Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Prescient Therapeutics's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Prescient Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Prescient Therapeutics's Price-to-Operating-Cash-Flow falls into.

Prescient Therapeutics Price-to-Operating-Cash-Flow Calculation

Prescient Therapeutics's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio	=	Share Price	/	Cash Flow from Operations per share (TTM)
	=	0.041	/	-0.009
	=

Prescient Therapeutics's Share Price of today is A$0.041.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Prescient Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.01.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio

Market Cap

Cash Flow from Operations

Prescient Therapeutics Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Prescient Therapeutics's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

Prescient Therapeutics (ASX:PTX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Prescient Therapeutics Ltd (ASX:PTX) » Definitions » Price-to-Operating-Cash-Flow

Comparable Companies

Traded in Other Exchanges

N/A

Address

Level 4, 100 Albert Road, South Melbourne, Melbourne, VIC, AUS, 3205

Website

https://www.ptxtherapeutics.com

Prescient Therapeutics Ltd is a clinical-stage oncology company. The company develops novel compounds for the treatment of a range of cancers in Australia. Its product in the pipeline includes OmniCAR; PTX-100 and PTX-200. OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product.

Prescient Therapeutics (ASX:PTX) Headlines

No Headlines